Optimal imaging and biopsy protocols for active surveillance in prostate cancer
Poster Session 75

Monday 20 July
14:00 - 15:30

Location: Purple Area, Room Elicium 1

Chairs: To be confirmed
To be confirmed
W.L. Loidl, Linz (AT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1030

Indication for active surveillance in the era of MRI-targeted biopsies
To be confirmed

1031

Does inclusion of MRI in active surveillance decrease the rate of discontinuation? A reflection of the use of MRI in the PRIAS study
By: Luiting H.B. 1, Remmers S. 1, Boevé E.R. 2, Zollo F. 3, Badenchini F. 3, Rannikko A. 4, Roobol M. 1, The PRIAS consortium
1Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 2Franciscus Gasthuis & Vlietland, Dept. of Urology, Rotterdam, The Netherlands, 3Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Urology, Milano, Italy, 4Helsinki University Hospital and University of Helsinki, Dept. of Urology, Helsinki, Finland

1032

Is it time to revise active surveillance protocols for men on active surveillance who have negative prostate findings on re-biopsy?
By: Beckmann K. 1, Singh S. 2, Sandhu P. 2, Santa Olalla A. 1, Dewan K. 1, Cathcart P. 2, Challacombe B. 2, Poppert R. 2, Dasgupta P. 2, Van Hemelrijck M. 1, Elhage O. 2
1Kings College London, Dept. of Translational Oncology and Urology Research (TOUR), London, United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, The Urology Centre, London, United Kingdom

1033

Are men with low risk prostate cancer but high PIRADS score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
To be confirmed

1034

Prognostic value of high PIRADS score lesions at mp-MRI of the prostate in men with low risk prostate cancer managed with active surveillance: Results from a single institution series
To be confirmed

* 1035

Predictors of negative targeted prostate biopsy despite PIRADS 4-5 lesions on multiparametric magnetic resonance imaging
To be confirmed
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1036</td>
<td>Predictors of clinically significant disease on systematic cores only in magnetic resonance imaging-guided prostate biopsy</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>1037</td>
<td>The significance of multiparametric magnetic resonance imaging in monitoring of prostate cancer patients on active surveillance</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>1038</td>
<td>The role of magnetic resonance in active surveillance for prostate cancer. The romas project: Four years experience in a randomized, prospective study</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>1039</td>
<td>Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>* 1040</td>
<td>Withdrawn</td>
<td></td>
</tr>
<tr>
<td>1041</td>
<td>Factors predicting active treatment free-survival: 10-year experience of active surveillance</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>1042</td>
<td>Role of age in a MRI-based active surveillance cohort: Association with clinical and radiological progression</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>1043</td>
<td>Comparison of different biopsy schedules among men on active surveillance: Analysis of the GAP3 global consortium database</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>

By: Beckmann K.¹, Bangma C.², Hellman J.², Santa Olalla A.¹, Nieboer D.², Bjartell A.³, Morgan T.⁴, Carroll P.⁵, Trock B.⁶, Valdagni R.⁷, Roobol M.², G.A.P.3⁸

¹Kings College London, Dept. of Translational Oncology and Urology Research (TOUR), London, United Kingdom, ²Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ³Skane Hospital, Dept. of Clinical Urology, Malmo, Sweden, ⁴University of Michigan, Dept. of Urological Surgery Improvement Collaborative, Michigan, United States of America, ⁵University of California San Francisco, Dept. of Urology, San Francisco, United States of America, ⁶John Hopkins University, The James Buchanan Brady Urology Institute, Baltimore, United States of America, ⁷Istituto Nazionale dei Tumori, Dept. of Radiation Oncology 1, Milano, Italy, ⁸Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance, Melbourne, Australia